|
1
|
Ahmed S, Johnson K, Ahmed O and Iqbal N:
Advances in the management of colorectal cancer: From biology to
treatment. Int J Colore Dis. 29:1031–1042. 2014. View Article : Google Scholar
|
|
2
|
László L: Predictive and prognostic
factors in the complex treatment of patients with colorectal
cancer. Magy Onkol. 54:383–394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sung JJ, Lau JY, Goh KL and Leung WK: Asia
Pacific Working Group on Colorectal Cancer: Increasing incidence of
colorectal cancer in Asia: Implications for screening. Lancet
Oncol. 6:871–876. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu T, Li Z, Gao CY and Cho CH: Mechanisms
of drug resistance in colon cancer and its therapeutic strategies.
World J Gastroenterol. 22:6876–6889. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shi W, Ye Z, Zhuang L, Li Y, Shuai W, Zuo
Z, Mao X, Liu R, Wu J, Chen S and Huang W: Olfactomedin 1
negatively regulates NF-kB signalling and suppresses the growth and
metastasis of colorectal cancer cells. J Pathol. 240:352–365. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yan H, Hu K, Wu W, Li Y, Tian H, Chu Z,
Koeffler HP and Yin D: Low expression of DYRK2 (Dual specificity
tyrosine phosphorylation regulated kinase 2) correlates with poor
prognosis in colorectal cancer. PLoS One. 11:e01599542016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y, Lin C, Liao G, Liu S, Ding J,
Tang F, Wang Z, Liang X, Li B, Wei Y, et al: MicroRNA-506
suppresses tumor proliferation and metastasis in colon cancer by
directly targeting the oncogene EZH2. Oncotarget. 6:32586–32601.
2015.PubMed/NCBI
|
|
8
|
Zhou FQ, Qi YM, Xu H, Wang QY, Gao XS and
Guo HG: Expression of EpCAM and Wnt/β-catenin in human colon
cancer. Genet Mol Res. 14:4485–4494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Phipps AI, Shi Q, Newcomb PA, Nelson GD,
Sargent DJ, Alberts SR and Limburg PJ: Associations between
cigarette smoking status and colon cancer prognosis among
participants in North central cancer treatment group phase III
trial N0147. J Clin Oncol. 31:2016–2023. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo J, Chen J, Deng ZL, Luo X, Song WX,
Sharff KA, Tang N, Haydon RC, Luu HH and He TC: Wnt signaling and
human diseases: What are the therapeutic implications? Lab Invest.
87:97–103. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bienz M and Clevers H: Linking colorectal
cancer to Wnt signaling. Cell. 103:311–320. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Basu S, Haase G and Ben-Ze'ev A: Wnt
signaling in cancer stem cells and colon cancer metastasis.
F1000Res. 5:pii: F1000 Faculty Rev. –699. 2016. View Article : Google Scholar
|
|
14
|
Kikuchi A: Canonical Wnt signaling pathway
and cellular responses. Clin Calcium. 23:799–807. 2013.(In
Japanese). PubMed/NCBI
|
|
15
|
Kirikoshi H, Sekihara H and Katoh M:
WNT10A and WNT6, clustered in human chromosome 2q35 region with
head-to-tail manner, are strongly coexpressed in SW480 cells.
Biochem Biophys Res Commun. 283:798–805. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yuan G, Regel I, Lian F, Friedrich T,
Hitkova I, Hofheinz RD, Ströbel P, Langer R, Keller G, Röcken C, et
al: WNT6 is a novel target gene of caveolin-1 promoting
chemoresistance to epirubicin in human gastric cancer cells.
Oncogene. 32:375–387. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Katoh M: WNT and FGF gene clusters
(review). Int J Oncol. 21:1269–1273. 2002.PubMed/NCBI
|
|
18
|
Lavery DL, Davenport IR, Turnbull YD,
Wheeler GN and Hoppler S: Wnt6 expression in epidermis and
epithelial tissues during Xenopus organogenesis. Dev Dyn.
237:768–779. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Galbraith RL, Poole EM, Duggan D, Muehling
J, Hsu L, Makar K, Xiao L, Potter JD and Ulrich CM: Polymorphisms
in WNT6 and WNT10A and colorectal adenoma risk. Nutr Cancer.
63:558–564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Na YJ, Jeon YJ, Suh JH, Kang JS, Yang KH
and Kim HM: Suppression of IL-8 gene expression by radicicol is
mediated through the inhibition of ERK1/2 and p38 signaling and
negative regulation of NF-kappaB and AP-1. Int Immunopharmacol.
1:1877–1887. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li X, Xu Y, Chen Y, Chen S, Jia X, Sun T,
Liu Y, Li X, Xiang R and Li N: SOX2 promotes tumor metastasis by
stimulating epithelial-to-mesenchymal transition via regulation of
WNT/β-catenin signal network. Cancer Lett. 336:379–389. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lustig B and Behrens J: The Wnt signaling
pathway and its role in tumor development. J Cancer Res Clin Oncol.
129:199–221. 2003.PubMed/NCBI
|
|
24
|
Kirikoshi H, Sekihara H and Katoh M:
Up-regulation of WNT10A by tumor necrosis factor alpha and
Helicobacter pylori in gastric cancer. Int J Oncol. 19:533–536.
2001.PubMed/NCBI
|
|
25
|
Mukherjee N, Bhattacharya N, Alam N, Roy
A, Roychoudhury S and Panda CK: Subtype-specific alterations of the
Wnt signaling pathway in breast cancer: Clinical and prognostic
significance. Cancer Sci. 103:210–220. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guillen-Ahlers H: Wnt signaling in renal
cancer. Curr Drug Targets. 9:591–600. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen GAJ, Wang M, Farley S, Lee LY, Lee LC
and Sawicki MP: Menin promotes the Wnt signaling pathway in
pancreatic endocrine cells. Mol Cancer Res. 6:1894–1907.
2008.PubMed/NCBI
|
|
28
|
Robinson DR, Zylstra CR and Williams BO:
Wnt signaling and prostate cancer. Curr Drug Targets. 9:571–580.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Larue L and Delmas V: The WNT/Beta-catenin
pathway in melanoma. Front Biosci. 11:733–742. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Modder UI, Oursler MJ, Khosla S and Monroe
DG: Wnt10b activates the Wnt, notch, and NFkB pathways in U2OS
osteosarcoma cells. J Cell Biochem. 112:1392–1402. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yuan G, Regel I, Lian F, Friedrich T,
Hitkova I, Hofheinz RD, Ströbel P, Langer R, Keller G, Röcken C, et
al: WNT6 is a novel target gene of caveolin-1 promoting
chemoresistance to epirubicin in human gastric cancer cells.
Oncogene. 32:375–387. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wieczorek M, Paczkowska A, Guzenda P,
Majorek M, Bednarek AK and Lamparska-Przybysz M: Silencing of Wnt-1
by siRNA induces apoptosis of MCF-7 human breast cancer cells.
Cancer Biol Ther. 7:268–274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jung YS, Jun S, Lee SH, Sharma A and Park
JI: Wnt2 complements Wnt/β-catenin signaling in colorectal cancer.
Oncotarget. 6:37257–37268. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang C, Ma R, Xu Y, Li N, Li Z, Yue J, Li
H, Guo Y and Qi D: Wnt2 promotes non-small cell lung cancer
progression by activating WNT/β-catenin pathway. Am J Cancer Res.
5:1032–1046. 2015.PubMed/NCBI
|
|
35
|
Chen H, Wang Y and Xue F: Expression and
the clinical significance of Wnt10a and Wnt10b in endometrial
cancer are associated with the Wnt/β-catenin pathway. Oncol Rep.
29:507–514. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cao LH, Li HT, Lin WQ, Tan HY, Xie L,
Zhong ZJ and Zhou JH: Morphine, a potential antagonist of cisplatin
cytotoxicity, inhibits cisplatin-induced apoptosis and suppression
of tumor growth in nasopharyngeal carcinoma xenografts. Sci Rep.
6:187062016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gialeli C, Theocharis AD and Karamanos NK:
Roles of matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sugimoto C, Fujieda S, Seki M, Sunaga H,
Fan GK, Tsuzuki H, Borner C, Saito H and Matsukawa S:
Apoptosis-promoting gene (bax) transfer potentiates sensitivity of
squamous cell carcinoma to cisplatin in vitro and in vivo. Int J
Cancer. 82:860–867. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee EH, Chari R, Lam A, Ng RT, Yee J,
English J, Evans KG, Macaulay C, Lam S and Lam WL: Disruption of
the Non-canonical WNT pathway in lung squamous cell carcinoma. Clin
Med Oncol. 2:169–179. 2008.
|
|
40
|
Ramel MC and Lekven AC: Repression of the
vertebrate organizer by Wnt8 is mediated by Vent and Vox.
Development. 131:3991–4000. 2004. View Article : Google Scholar : PubMed/NCBI
|
